Biocon Biologics secures market entry date for Denosumab biosimilars in Europe, Rest of the World
The agreement allows Biocon Biologics to commercialize both its Denosumab biosimilars (Vevzuo and Evfraxy) in Europe starting December 2, 2025
The agreement allows Biocon Biologics to commercialize both its Denosumab biosimilars (Vevzuo and Evfraxy) in Europe starting December 2, 2025
Phase one of the expansion will convert an existing hall into an ISO 7-certified cleanroom for GMP-compliant production
The study, titled “A Large-Scale Efficacy Trial of a Resilience Training Program for First Responders,” will enroll 800 first responders in New York and Texas
The hospital has already onboarded 200+ experienced doctors and is expected to generate 5,000–7,000 jobs
The proposed transaction will be effected as a share swap
The initiative aims to connect startups and tech companies with its business units,
The FDA setback highlights ongoing tensions between patient needs, regulatory processes, and the use of real-world evidence in evaluating treatments for rare diseases
From material selection to cooling tower management, every small decision affects long-term equipment reliability
The upcoming state-of-the art 400+ bed facility is set to come up at an approximate cost of Rs 500 crore
Subscribe To Our Newsletter & Stay Updated